BRAF and non-small cell lung carcinoma: Above targeted therapy, Dudnik E et al. reported that ICIs have favorable activity both in BRAF V600E- and BRAF non-V600E-mutant NSCLC patients, as BRAF-mutated patients have high levels of PD-L1 expression, low/intermediate TMB and microsatellite-stable status [318].